Scilex Holding Company Reports Q2 2026 Financial Results with $115M Net Loss

Scilex Holding Company reported its financial results for the second quarter of 2026, revealing a net revenue of $7.6 million, a decrease from $9.9 million in the same period last year. For the first half of 2026, the company generated $16.3 million in revenue, up from $14.9 million in the first half of 2025. The decline in quarterly revenue was primarily attributed to a $4.0 million drop in sales of its flagship product, ZTlido, which was partially offset by $1.5 million in contract revenue from Vivasor and a slight increase in sales of ELYXYB. The company’s accumulated deficit reached $1.1 billion as of June 30, 2026, reflecting ongoing investments in product development and commercialization.

Operating expenses for the second quarter totaled $37.1 million, compared to $30.4 million in the prior year, driven by increased selling, general, and administrative costs, which rose by approximately $8.1 million. Research and development expenses decreased to $3.3 million from $6.2 million, largely due to reduced costs associated with the KDS2010 license acquisition. The company reported a net loss of $115.0 million for the quarter, significantly higher than the $44.0 million loss in the same quarter of 2025. For the first half of 2026, the net loss was $160.6 million, compared to $70.1 million in the previous year.

In terms of strategic developments, Scilex has been actively pursuing acquisitions and product launches. The company launched ELYXYB in the U.S. in April 2023 and is developing three product candidates, including SP-102, SP-103, and SP-104, which are in various stages of clinical trials. The company also reported a significant increase in its liabilities, with total liabilities amounting to $564.1 million as of June 30, 2026, compared to $576.7 million at the end of 2025. This increase was primarily due to accrued rebates and fees, which rose to $256.1 million.

Scilex's operational metrics indicate a focus on expanding its market presence, with a dedicated sales force of approximately 34 employees targeting 10,000 healthcare providers. The company is also exploring additional funding avenues to support its operations, including potential equity offerings and collaborations. However, management expressed substantial doubt about the company's ability to continue as a going concern, given its negative working capital of $476.0 million and limited cash reserves of approximately $0.6 million.

Looking ahead, Scilex plans to continue investing in its marketing and research efforts while seeking additional funding to support its growth strategy. The company is also evaluating its cryptocurrency treasury strategy, which involves investing in Bitcoin and other digital assets. The success of these initiatives will be critical for Scilex as it aims to achieve profitability and navigate the challenges of the biopharmaceutical market.